he eXchange Unit Technology (XUT) developed by RhabdoTec offers a novel, quick and cost-effective alternative for the development and production of pharmaceutical agents, for example, antibiotics, anti-cancer drugs and immunosuppressants: thanks to this new biotechnological process, microorganisms (to be more specific, non-ribosomal peptide synthetases) can be specifically reprogrammed for the development and production of novel active agents. The XUT is particularly suitable for synthesizing cyclic peptides with unusual building blocks – chemical synthesis has not been able to produce at reasonable cost, so far. This makes the XUT very attractive for the pharmaceutical industry while at the same time being beneficial for human health.